KLK3 and pachyonychia congenita: Serum PSA is a powerful screening marker [8] and has helped reduce the metastatic PCs and mortality in PC patients [9, 10]; however, the PSA test for PC prediction lacks a balance between sensitivity and specificity to the extent that when one aspect reaches 80%, the other decreases to 30% [11].